Skip to main
BTSG

BTSG Stock Forecast & Price Target

BTSG Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrightSpring Health Services Inc. has demonstrated impressive growth in its OP Rehab segment, achieving growth in the double-digit percentage range while generating attractive margins. The Pharmacy Solutions segment notably reported a substantial increase in specialty revenue, projected at approximately $2.6 billion for 2025, reflecting a year-over-year growth of 43%, alongside a promising EBITDA margin increase. Additionally, management expresses confidence in enhancing margins and EBITDA through strategic acquisitions, while the Provider Services division benefits from stable reimbursement trends and a notable 15% year-over-year increase in home health average daily census in 4Q:25.

Bears say

BrightSpring Health Services Inc. faces potential revenue challenges due to the vulnerability of its clients and their budget priorities, which may weaken its business performance. Additionally, concerns regarding reduced prescription writing and drug utilization by healthcare professionals could adversely impact the company's revenues, operating results, and cash flows. The company's significant debt load further constrains its ability to invest in growth, potentially limiting expansion opportunities in an increasingly competitive market.

BTSG has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BrightSpring Health Services Inc (BTSG) Forecast

Analysts have given BTSG a Buy based on their latest research and market trends.

According to 9 analysts, BTSG has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BrightSpring Health Services Inc (BTSG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.